share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/19 05:46
牛牛AI助理已提取核心訊息
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
2024年3月15日，CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼完成了一項涉及公司普通股的股票交易。庫爾卡尼通過行使衍生證券以每股19.12美元的價格收購了20,000股股票。同一天，他在兩次單獨的公開市場交易中共出售了20,000股股票。第一次出售包括10,613股股票，每股價格爲71.9693美元，第二次出售涉及以每股73.0604美元的價格出售的9,387股股票。這些交易之後，庫爾卡尼在CRISPR Therapeutics的直接持股量爲208,122股。已處置股票的總市值約爲1,449,628美元。此外，庫爾卡尼通過間接實益所有權結構庫爾卡尼2023 GRAT間接持有20萬股股票的權益。
2024年3月15日，CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼完成了一項涉及公司普通股的股票交易。庫爾卡尼通過行使衍生證券以每股19.12美元的價格收購了20,000股股票。同一天，他在兩次單獨的公開市場交易中共出售了20,000股股票。第一次出售包括10,613股股票，每股價格爲71.9693美元，第二次出售涉及以每股73.0604美元的價格出售的9,387股股票。這些交易之後，庫爾卡尼在CRISPR Therapeutics的直接持股量爲208,122股。已處置股票的總市值約爲1,449,628美元。此外，庫爾卡尼通過間接實益所有權結構庫爾卡尼2023 GRAT間接持有20萬股股票的權益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。